# A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

> **NCT03668119** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 212 (actual)

## Conditions studied

- Pan Tumor

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03668119
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-31
- **Primary completion:** 2022-05-03
- **Final completion:** 2023-08-02
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668119, "A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03668119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*